0001156039-24-000026.txt : 20240305 0001156039-24-000026.hdr.sgml : 20240305 20240305162108 ACCESSION NUMBER: 0001156039-24-000026 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOUDREAUX GAIL CENTRAL INDEX KEY: 0001287920 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 24720766 MAIL ADDRESS: STREET 1: GENZYME CORP. STREET 2: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 4 1 wk-form4_1709673632.xml FORM 4 X0508 4 2024-03-01 0 0001156039 Elevance Health, Inc. ELV 0001287920 BOUDREAUX GAIL 220 VIRGINIA AVENUE INDIANAPOLIS IN 46204 1 1 0 0 President and CEO 0 Common Stock 2024-03-01 4 F 0 19256 499.11 D 117777 D Common Stock 2024-03-01 4 A 0 8415 0 A 126192 D Common Stock 2024-03-01 4 A 0 34517 0 A 160709 D Common Stock 60 I Shares Held in Spouse's Revocable Trust Employee Stock Option (Right to Buy) 499.11 2024-03-01 4 A 0 32480 0 A 2034-03-01 Common Stock 32480 32480 D PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Represents restricted share units. Restrictions lapse as follows: 2,805 shares each on 3/1/2025, 3/1/2026, and 3/1/2027. Represents performance based restricted share units. Restrictions lapse on 3/1/2024. Balance includes 392.27 shares acquired on 3/24/2023, 389.71 shares acquired on 6/23/2023 and 388.21 shares acquired on 9/23/2023 through a dividend reinvestment plan. The option represents a right to purchase a total of 32,480 shares, and is exercisable in one installment of 10,826 shares and two installments of 10,827 shares each, beginning on 3/1/2025, which is the one-year anniversary of the option grant date. /s/ Kathleen S. Kiefer, Attorney in fact 2024-03-05